Loading clinical trials...
Loading clinical trials...
Discover 17,687 clinical trials near Maryland. Find research studies in your area.
Showing 8521-8540 of 17,687 trials
NCT01950377
Background: \- Previous research has shown that dopamine, a brain chemical, is involved in decision making. Different genes influence how much dopamine people have in their brains and how that affects their behavior. Researchers will study if genes associated with dopamine affect decision making and impulsiveness. All participants will take tests; some will have brain images taken. Researchers will study the test responses and images; they will look for how differences in these genes affect different types of decision making. Objectives: \- To see if genes involved in a brain chemical, dopamine, are related to impulsiveness on behavioral tests. Eligibility: \- Healthy adults ages 18 to 55. Design: * Participants will be screened with a medical history and physical exam. * All participants in this study will have at least 1 outpatient visit to the NIH Clinical Center. Each visit will last 2 4 hours. At the first visit: * A blood sample will be taken only from participants that have not been previously enrolled in 95-M-0150 * Participants will be given tests of their memory, attention, concentration, and thinking. * Some participants will have a second visit. It will be scheduled as soon as possible after the first. At the second visit: * Participants will have an MRI (magnetic resonance imaging). They will have to lie in a scanner for up to 2 hours. The MRI uses magnets, radio waves, and computers to produce detailed pictures of the brain. * Participants will repeat the tests from the first visit. Some will be done during the MRI.
NCT00001563
The prognosis of AIDS-related Non-Hodgkin's lymphoma is poor, especially in the relapsed setting. There is no standard treatment, and the few small studies that have been conducted have reported dismal outcomes. The purpose of this study is to pilot the use of EPOCH plus rituximab in previously treated AIDS-related lymphoma. Clinical endpoints of the study include toxicity and response. Progression-free and overall survival will be measured. Tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation, c-myc and EBV when possible.